

Pediatrics HIV Performance Measures

#	%	Measure	Data Elements	Numerator	Denominator	Exclusions
1	Not measuring in 2011	Percentage of pediatric patients with HIV infection on ARVs who were assessed and counseled for adherence two or more times in the measurement year	Is the pediatric patient HIV-infected? (Y/N) a. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? If yes, was the patient on ARVs?(Y/N) 1. If the patient was on ARVs, did the patient and/or the parent/guardian (as appropriate) receive adherence counseling during the measurement year? (Y/N). a. If yes, list the dates of these visits.	Number of HIV-infected pediatric patients, as part of their primary care, who were assessed and counseled for adherence two or more times at least three months apart	Number of HIV-infected pediatric patients on ARV therapy who had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Patients newly enrolled in care during last six months of the year. Patients who initiated ARV therapy during last six months of the year
2	100%	Percentage of pediatric patients with HIV infection who met age-specific eligibility criteria were prescribed ARV therapy during the measurement year	1. Is the pediatric patient HIV-infected? (Y/N) a. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) i. If yes, did the patient meet the eligibility criteria for ARV therapy? (Y/N) 1. If yes, was the patient prescribed ARV therapy? (Y/N)	Number of HIV-infected pediatric patients who were prescribed ARV therapy	Number of HIV-infected pediatric patients who: 1) had a medical visit with a provider with prescribing privileges ³ at least once in the measurement year; AND 2) met the following age-specific eligibility criteria ² : <12 mos. = All HIV-infected pediatric patients 1 to <5 yrs = AIDS or significant HIV-related symptoms; or CD4 <25% regardless of symptoms or HIV RNA level >5 yrs = AIDS or significant HIV-related symptoms; or CD4<350 cells/mm ³ ; 3) OR, are currently on ARV therapy	1. Patients newly enrolled in care during last four months of the measurement year

3	70%	Percentage of pediatric patients with HIV infection who had at least three (3) CD4 values performed in the measurement year	1. Is the pediatric patient HIV-infected? (Y/N) a. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) i. If yes, did the patient have three or more CD4 values performed at least three months apart during the measurement year? (Y/N) 1. If yes, list the dates the specimens were obtained.	Number of HIV-infected pediatric patients who had three or more CD4 values performed at least three months apart during the measurement year	Number of HIV-infected pediatric patients who had a medical visit with a provider with prescribing privileges at least once in the measurement year	Pediatric patients with HIV infection newly enrolled in care during the last nine months of the measurement year
4	100%	Percentage of HIV- infected or exposed pediatric patients who had developmental surveillance documented in the measurement year	1. Is the pediatric patient HIV-infected or exposed? (Y/N) a. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) i. If yes, was developmental surveillance documented in the measurement year? (Y/N) 1. If yes, list the date.	Number of HIV-infected or exposed pediatric patients who had developmental surveillance documented in the measurement year	Number of HIV-infected or exposed pediatric patients who had a medical visit with provider with prescribing privileges at least once in the measurement year	None
5	100%	Percentage of exposed infants born to HIV-infected women who received recommended virologic diagnostic testing for exclusion of HIV infection in the measurement year	1. Was the patient 6-12 months of age at any point in the measurement year? (Y/N) a. If yes, was the infant born to an HIV-infected woman? (Y/N) i. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) 1. If yes, did the infant have documentation of receiving at least two virologic diagnostic tests at recommended time points2 to definitively exclude HIV infection? (Y/N) a. If yes, list dates.	Number of HIV-perinatally exposed infants who had at least two virologic diagnostic tests performed at appropriate time points by age of six months to definitively exclude HIV infection	Number of HIV-perinatally exposed infants who: (a)were 6-12 months of age at any point in the measurement year; and (b) who had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Patients who were newly enrolled after six months of age 2. Patients diagnosed with HIV infection

6	80%	Percentage of adolescents with HIV infection who had a discussion about health care transition planning documented in the health record in the measurement year	1. Is the adolescent HIV-infected? (Y/N) a. If yes, is the adolescent > 17 years (Y/N) i. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) 1. If yes, is a discussion about health care transition documented in the health record in the measurement year? (Y/N) a. If yes, list the date	Number of HIV-infected adolescents who had a discussion about health care transition planning documented in the health record in measurement year	Number of HIV-infected adolescents who: (a) were > 17 years old in the measurement year, and (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Adolescents who were newly diagnosed with HIV infection in the measurement year
7	100%	Percentage of pediatric patients with HIV infection who had an HIV drug resistance test performed before initiation of ARV therapy if therapy started during the measurement year	1. Is the pediatric patient HIV-infected? (Y/N) a. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) i. If yes, was ARV therapy prescribed during the measurement year for the first time? (Y/N) 1. If yes, was an HIV drug resistance test performed at any time prior to prescribing ARV therapy? (Y/N) a. If yes, list date.	Number of HIV-infected pediatric patients who had an HIV drug resistance test performed at any time before initiation of ARV therapy	Number of HIV-infected pediatric patients who: (a) were prescribed ARV therapy during the measurement year for the first time; and (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year	None
8	100%	Percentage of pediatric patients with HIV infection on ARV therapy who had a lipid panel during the measurement year	1. Is the pediatric patient HIV-infected? (Y/N) a. If yes, did the patient have a medical visit with a provider with prescribing privileges during the measurement year? (Y/N) i. If yes, was the patient on ARV therapy? (Y/N) 1. If yes, did he/she have a lipid panel performed during the measurement year? (Y/N)	Number of HIV-infected pediatric patients who had a lipid panel performed in the measurement year	Number of HIV-infected pediatric patients who: (a) are on ARV therapy; and (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Patients less than 12 months of age at end of measurement year

9	70%	Percentage of pediatric patients with HIV infection who had three or more medical visits in an HIV care setting in the measurement year	1. Is the pediatric patient HIV-infected? (Y/N) a. If yes, was the patient seen by a provider with prescribing privileges at least once in an HIV care setting during the measurement year? (Y/N) i. If yes, did the patient have at least three medical visits at least three months apart in the measurement year? (Y/N) 1. If yes, list the dates of these visits.	Number of HIV-infected pediatric patients who had a medical visit with a provider with prescribing privileges in an HIV care setting three or more times at least three months apart in the measurement year	Number of HIV-infected pediatric patients who had a medical visit with a provider with prescribing privileges in an HIV care setting at least once in the measurement year	1. Pediatric patients newly enrolled in care during the last nine months of the measurement year
10	Not measuring in 2011	Percentage of pediatric patients with HIV infection who have had at least one dose of Measles, Mumps & Rubella (MMR) vaccine administered between 12-24 months of age	1. Is the pediatric patient HIV-infected? (Y/N) a. If yes, was the patient > 2 years and < 3 years of age at any time in the measurement year? (Y/N) i. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) 1. If yes, did the patient receive at least one dose of MMR vaccine between 12-24 months of age? (Y/N) a. If yes, list the date of immunization or serology	Number of HIV-infected pediatric patients who had at least one dose of MMR administered between 12-24 months of age	Number of HIV-infected pediatric patients > 2 years and < 3 years of age who had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Pediatric patients with CD4 <15% between 12-24 months of age 2. Pediatric patients newly enrolled after 2 yrs of age
11	Not measuring in 2011	Percentage of infants born to HIV-infected women who were prescribed ZDV prophylaxis for HIV within 12 hours of birth during the measurement year	Was the infant born to an HIV-infected woman during the measurement year? (Y/N) a. If yes, was the infant seen by a provider with prescribing privileges in an HIV setting during the measurement year? (Y/N) i. If yes, was ZDV prophylaxis prescribed within 12 hours of birth during the measurement year? (Y/N) 1. If yes, list the date.	Number of infants born to HIV-infected women who were prescribed ZDV prophylaxis within 12 hours of birth during the measurement year	Number of infants who: (a) were born to HIV-infected women during the measurement year; and (b) had a visit with a provider with prescribing privileges in an HIV setting during the measurement year	

12	Not measuring in 2011	Percentage of eligible infants with HIV-exposure who were prescribed PCP prophylaxis in the measurement year	<p>Was the infant seen by a provider with prescribing privileges during the measurement year? (Y/N) a. Was the infant HIV-exposed (born to an HIV-infected woman)? (Y/N) i. If yes, was the infant > 6 weeks of age at any point during the measurement year? (Y/N) 1. If yes, was HIV presumptively excluded by six weeks of age? (Y/N)</p> <p>a. If no, was the infant prescribed PCP prophylaxis during the measurement year? (Y/N) i. If yes, list the date</p>	Number of HIV-exposed infants who were prescribed PCP prophylaxis during the measurement year	Number of HIV-exposed infants: (a) in whom HIV infection has not been presumptively excluded by 6 weeks of age; and (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Patients who are diagnosed with HIV infection
13	100%	Percentage of eligible infants and children with HIV infection who were prescribed PCP prophylaxis in the measurement year	<p>1. Was the infant or child seen by a provider with prescribing privileges during the measurement year? (Y/N) a. If yes, is the infant or child HIV-infected? (Y/N) i. If yes, is the infant or child > 6 weeks of age? (Y/N) 1. If yes, did the infant or child meet the age-specific eligibility criteria? (Y/N)</p> <p>a. If yes, was the infant or child prescribed PCP prophylaxis during the measurement year? (Y/N) i. If yes, list the date.</p>	Number of HIV-infected infants or children who were prescribed PCP prophylaxis during the measurement year	Number of: (a) HIV-infected infants or children > 6 weeks of age who meet the following age-specific eligibility criteria: <12 months = All HIV-infected infants regardless of CD4 count 1-5 yrs = CD4<500 cells/mm ³ or CD4%<15% >6 yrs = CD4<200 cells/mm ³ or CD4%<15% AND (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year	1. Patients with CD4 values below age appropriate threshold repeated within 3 months that rose above age appropriate threshold

14	80%	Percentage of pediatric/adolescent patients with HIV infection who know their HIV status or for whom there is a documented discussion about disclosure in the measurement year	1. Is the pediatric/adolescent patient HIV-infected? (Y/N) a. If yes, is the child > 12 years old? (Y/N) i. If yes, was the patient seen by a provider with prescribing privileges during the measurement year? (Y/N) 1. If yes, does the child know of his/her HIV status or is there a documented discussion about disclosure in the measurement year? (Y/N) a. If yes, list date.	Number of HIV-infected pediatric/adolescent patients who know their status or for whom the provider and guardian had a documented discussion about disclosure	Number of HIV-infected pediatric/adolescent patients who: (a) were > 12 years old at the beginning of the measurement year, and (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year	None
15	Not measuring in 2011	Percentage of pediatric patients with HIV infection who received testing with results documented for latent tuberculosis infection (LTBI) during the measurement year	1. Is the pediatric patient HIV-infected? (Y/N) a. Did the patient have a medical visit with a provider with prescribing privileges during the measurement year? (Y/N) i. If yes, has the patient ever had previous treatment for TB disease or previous documented positive TST? (Y/N) 1. If no, has the patient been tested for LTBI with a TST during the measurement year? (Y/N) a. If yes, are the results documented? (Y/N)	Number of pediatric patients who received documented testing for LTBI with tuberculin skin test (TST) during the measurement year	Number of HIV-infected pediatric patients who: (a) do not have a history of previous documented treatment of TB disease or previous documented positive TST; and (b) had a medical visit with a provider with prescribing privileges at least once in the measurement year.	